Viridian Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 12, 2022
Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced it will report financial results for Q1 2022, ending March 31, after market close on May 12, 2022. A conference call will take place at 4:30 p.m. ET on the same day, accessible via phone or webcast. The company's focus is on developing treatments for serious diseases, with lead candidate VRDN-001 targeting insulin-like growth factor-1 receptor for thyroid eye disease, and VRDN-002, an extended half-life anti-IGF-1R antibody for convenient subcutaneous administration.
- Focus on developing innovative treatments for underserved diseases.
- Lead product candidate VRDN-001 targets a clinically validated disease, thyroid eye disease.
- None.
WALTHAM, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced it will report its financial results from the first quarter ended March 31, 2022, after the financial markets close on Thursday, May 12, 2022.
The Company’s management team is scheduled to host a conference call at 4:30 p.m. ET on Thursday, May 12, 2022. To access the call, please dial 1-877-270-2148 in the U.S. or 1-412-902-6510 outside the U.S. and ask for the Viridian call. To access the live webcast, please visit the “Events” page in the Investors section of the Viridian Therapeutics, Inc. website. Following the live webcast, an archived version of the call will be available on the website.
Thursday, May 12 @ 4:30 p.m. ET
| Domestic: | 1-877-270-2148 |
| International: | 1-412-902-6510 |
| Webcast: | Webcast Link |
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED). Viridian’s second product candidate, VRDN-002, is a distinct anti-IGF-1R antibody that incorporates half-life extension technology and is designed to support administration as a convenient, low-volume, subcutaneous injection. TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids. Viridian is based in Waltham, Massachusetts.
Investor and Media Contact:
John Jordan
Viridian Therapeutics
Vice President, Investor Relations
& Corporate Communications
617-272-4691
IR@viridiantherapeutics.com
FAQ
When will Viridian Therapeutics report its Q1 2022 financial results?
What are the key product candidates of Viridian Therapeutics?
What time is the Viridian Therapeutics conference call on May 12, 2022?
How can I access the Viridian Therapeutics conference call?
